NCT07087002View on ClinicalTrials.gov

GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults

PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 28, 2025

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2027

Conditions
MedulloblastomaCentral Nervous System Embryonal TumorRefractory MedulloblastomaRecurrent MedulloblastomaPediatric Brain TumorEmbryonal Tumor With Multilayered Rosettes (ETMR)PineoblastomaAtypical Teratoid/Rhabdoid Tumor (ATRT) of the CNSCNS NeuroblastomaFOXR2-activated
Interventions
BIOLOGICAL

GPC2-CAR T cells

Autologous T cells transduced with retroviral vector encoding a second-generation GPC2-targeted chimeric antigen receptor (GPC2-CAR), administered intracerebroventricularly. Up to 8 doses are given every 28 days, following an intrapatient dose escalation schema.

DRUG

Fludarabine

Administered as part of a lymphodepleting chemotherapy regimen prior to GPC2-CAR T cell infusion. Dose: 30 mg/m²/day for 3 days.

DRUG

Cyclophosphamide

Administered with fludarabine for lymphodepletion. Dose: 500 mg/m²/day for 3 days.

Trial Locations (1)

94304

RECRUITING

Lucile Packard Children's Hospital Stanford, Palo Alto

All Listed Sponsors
lead

Stanford University

OTHER